Owlet Announces Proposed Public Offering
LEHI, Utah–(BUSINESS WIRE)–Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announced it intends... Read more.
Anthem BCBS Foundation Distributes $300,000 to Three Food Banks in VA to Expand ‘Food as Medicine’ Initiatives Across the State
RICHMOND, Va.–(BUSINESS WIRE)–Anthem Blue Cross and Blue Shield Foundation in Virginia, a philanthropic arm of Elevance Health Foundation, announced... Read more.
Franklin Resources, Inc. Announces Month-End Assets Under Management
SAN MATEO, Calif.–(BUSINESS WIRE)–Franklin Resources, Inc. (Franklin Templeton) (NYSE: BEN) today reported preliminary month-end assets under management... Read more.
AM Best Withdraws Credit Ratings of Consolidated National Insurance Company
OLDWICK, N.J.–(BUSINESS WIRE)–#insurance—AM Best has withdrawn the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit... Read more.
Net Asset Value Restatement for Simplify Aggregate Bond ETF (AGGH) & Simplify Volatility Premium ETF (SVOL)
NEW YORK–(BUSINESS WIRE)–Simplify Asset Management Inc. announces that the previously disclosed net asset value (NAV) per share of the Simplify Aggregate... Read more.
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan demonstrated meaningfully greater magnitude of progression-free survival benefit in patients with this... Read more.
Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan demonstrated meaningfully greater magnitude of progression-free survival benefit in patients with this... Read more.
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
Summit to Initiate HARMONi-7, a Phase III Trial in First-Line PD-L1 High, Advanced NSCLC, in Early 2025 Ivonescimab Is the First Drug to Achieve Clinically Meaningful... Read more.
Coalition Announces Reinsurance Intermediary Coalition Re
Coalition Re to Offer Active Cyber Reinsurance via Two Products Supported by Aspen-led Capacity SAN FRANCISCO–(BUSINESS WIRE)–Coalition, the world’s... Read more.
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Placebo at Weeks 24 and 48 Responder Analysis... Read more.